Table 2.
Antibiotic resistant profile of Pseudomonas aeruginosa collected from hospitalized patients of four hospitals in Iran based on source of isolation
| source | number of isolate |
number (%) resistant isolates
|
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PTZ | CIP | MEM | IMI | ATM | CRO | CAZ | CPM | GM | TN | AK | ||
| burn exudate | 53 | 37(69.8) | 34(64.15) | 36(67.92) | 35(66.03) | 41(77.35) | 41(77.35) | 31(58.49) | 37(69.81) | 35(66.03) | 35(66.03) | 33(62.26) |
| urine | 48 | 12(25) | 16(33.33) | 17(35.41) | 17(35.41) | 14(29.16) | 30(62.50) | 13(27.08) | 13(27.08) | 17(35.41) | 15(31.25) | 13(27.08) |
| sputum | 29 | 7(24.13) | 9(31.03) | 11(37.93) | 10(34.48) | 8(27.58) | 18(62.06) | 8(27) | 8(27.58) | 8(27.58) | 7(24.13) | 6(20.68) |
| blood | 23 | 4(17.39) | 1(4.34) | 4(17.39) | 3(13.04) | 4(17.39) | 12(52.17) | 3(13.04) | 4(17.39) | 4(17.39) | 2(8.69) | 1(4.34) |
| wound | 22 | 3(13.63) | 6(27.27) | 5(22.72) | 5(22.72) | 7(31.81) | 14(63.63) | 6(27.27) | 5(2.72) | 5(22.72) | 5(22.72) | 5(22.72) |
| eye | 14 | 1(7.14) | 1(7.14) | 6(42.85) | 5(35.71) | 5(35.71) | 8(57.14) | 1(7.14) | 1(7.14) | 1(7.14) | 1(7.14) | 1(7.14) |
| others | 19 | 2(10.52) | 3(15.78) | 7(36.84) | 7(36.84) | 5(26.31) | 11(57.89) | 2(10.52) | 3(15.78) | 3(15.78) | 2(10.52) | 3(15.78) |
| total | 208 | 66(31.73) | 70(33.65) | 86(41.34) | 82(39.42) | 84(40.38) | 134(64.42) | 64(30.76) | 71(34.13) | 73(35.09) | 67(32.21) | 62(29.80) |
Amikacin (AK), Tobramycin (TN), Gentamicin (GM), cefepime (CPM), ceftazidime (CAZ), ceftriaxone (CRO), aztreonam (ATM), imipenem (IMI), meropenem (MEM), ciprofloxacin (CIP), piperacillin/tazobactam (PTZ)